Ascendis Pharma A/S (ASND)
NASDAQ: ASND · Real-Time Price · USD
142.67
+1.72 (1.22%)
Oct 4, 2024, 4:00 PM EDT - Market closed
Ascendis Pharma Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Ascendis Pharma stock have an average target of 195, with a low estimate of 140 and a high estimate of 289. The average target predicts an increase of 36.68% from the current stock price of 142.67.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ASND stock from 13 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '24 | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 3 | 4 | 4 | 5 | 6 |
| Buy | 4 | 4 | 4 | 4 | 4 | 6 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 10 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Strong Buy Maintains $175 → $191 | Strong Buy | Maintains | $175 → $191 | +33.88% | Sep 23, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $264 → $289 | Buy | Maintains | $264 → $289 | +102.57% | Sep 17, 2024 |
| Citigroup | Citigroup | Strong Buy Maintains $178 → $207 | Strong Buy | Maintains | $178 → $207 | +45.09% | Sep 17, 2024 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $191 → $205 | Buy | Maintains | $191 → $205 | +43.69% | Sep 17, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $180 → $190 | Buy | Reiterates | $180 → $190 | +33.17% | Sep 17, 2024 |
Financial Forecast
Revenue This Year
309.72M
from 266.72M
Increased by 16.12%
Revenue Next Year
580.55M
from 309.72M
Increased by 87.44%
EPS This Year
-6.31
from -8.55
EPS Next Year
-2.87
from -6.31
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 439.1M | 881.0M | 1.8B | ||
| Avg | 309.7M | 580.6M | 1.1B | ||
| Low | 259.1M | 456.4M | 782.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 64.6% | 184.4% | 213.8% | ||
| Avg | 16.1% | 87.4% | 85.7% | ||
| Low | -2.9% | 47.4% | 34.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.77 | 2.33 | 4.88 | ||
| Avg | -6.31 | -2.87 | 2.06 | ||
| Low | -7.81 | -6.59 | -1.27 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.